AbbVie(US:ABBV)2024-10-30 11:43Form 8-K Current Report (October 3, 2024) Item 2.02 Results of Operations and Financial Condition AbbVie updated its full-year and Q3 2024 adjusted diluted EPS guidance due to an estimated $82 million pre-tax acquired IPR&D and milestones expense impacting Q3 earnings by $0.04 per share - Third quarter 2024 earnings are expected to include $82 million in pre-tax acquired IPR&D and milestones expense4 - This expense is projected to have an unfavorable impact of $0.04 on both GAAP and adjusted non-GAAP diluted earnings per share for Q3 20244 Adjusted Diluted EPS Guidance | Guidance Period | Adjusted Diluted EPS Range | | :--- | :--- | | Full-Year 2024 | $10.67 - $10.87 | | Q3 2024 | $2.88 - $2.92 | - AbbVie clarifies it does not forecast acquired IPR&D and milestones expense due to the uncertainty of timing and occurrence5 Forward-Looking Statements This section provides a standard safe harbor statement, noting that forward-looking statements are subject to risks and uncertainties detailed in the 2023 Annual Report on Form 10-K, with no obligation for public updates - The report includes forward-looking statements subject to risks and uncertainties under the Private Securities Litigation Reform Act of 19957 - Investors are directed to Item 1A, "Risk Factors," of AbbVie's 2023 Annual Report on Form 10-K for operational risk factors7 - AbbVie disclaims any obligation to publicly release revisions to forward-looking statements, except as required by law7 Item 9.01 Financial Statements and Exhibits This section lists exhibits filed with the Form 8-K, primarily Exhibit 99.1, which contains updated 2024 guidance, noting that the information is furnished rather than filed for legal purposes - Exhibit 99.1, containing guidance inclusive of acquired IPR&D and milestones expense, is furnished with this report68 - The information in this report and its exhibits is not considered "Filed" under Section 18 of the Securities Exchange Act of 1934, limiting certain legal liabilities6